Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Takeda Pharmaceutical Ltd ADR
(NY:
TAK
)
13.57
-0.13 (-0.95%)
Streaming Delayed Price
Updated: 11:01 AM EDT, Jul 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Takeda Pharmaceutical Ltd ADR
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Takeda Receives FDA Approval to Expand the Use of HYQVIA® to Treat Primary Immunodeficiency in Children
April 11, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
April 11, 2023
We're starting off the day with a breakdown of the biggest pre-market stock movers traders will want to keep an eye on Tuesday!
Via
InvestorPlace
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
April 11, 2023
From
Centogene NV
Via
GlobeNewswire
Takeda Pharmaceutical Ltd. (NYSE: TAK) Highlighted for Surprising Price Action
April 06, 2023
Via
Investor Brand Network
Zoetis Stock Shows Rising Relative Strength Upgrades
February 17, 2023
Zoetis shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 81.
Via
Investor's Business Daily
Zoetis Stock Shows Healthy Growth Along With Puppies, Kittens
April 10, 2023
Zoetis stock is trying to complete a flat base with a 176.76 buy point. See if it can break out. Its stock got an upgrade Monday
Via
Investor's Business Daily
Week In Review: Suzhou Duality Out-Licenses Two ADCs To BioNTech In $1.7 Billion Deal
April 08, 2023
Duality Biologics out-licensed global rights (ex-China) for two ADC candidates to BioNTech, Pfizer’s partner, for one of the two original COVID-19 vaccines in a deal worth $170 million upfront and up...
Via
Talk Markets
The Byzantine Adderall Shortage Puts Teva And Others In The Hot Seat
April 05, 2023
Millions of people are scrambling to get their ADHD medication. Here's why.
Via
Investor's Business Daily
Etsy To Rally Around 30%? Here Are 10 Other Analyst Forecasts For Tuesday
April 04, 2023
B of A Securities cut the price target for Stem, Inc. (NYSE: STEM) from $9 to $5. B of A Securities analyst Julien Dumoulin-Smith downgraded the stock from Neutral to Underperform. Stem shares fell...
Via
Benzinga
Takeda Announces New U.S. Corporate Social Responsibility (CSR) Program Partners
April 03, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer
March 30, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Takeda Announces Results From Phase 4 Vedolizumab Study in Patients With Chronic Pouchitis Published in New England Journal of Medicine
March 30, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
March 30, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Zoetis Stock Sees IBD Relative Strength Rating Improve To 73
March 27, 2023
Zoetis stock had its Relative Strength Rating upgraded to 73 Monday -- a nice improvement, but still shy of the 80-plus score you look for.
Via
Investor's Business Daily
BioLife Plasma Services Opens its 200th Plasma Donation Center in the U.S.
March 27, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Week In Review: HighlightLL Pharma Out-Licenses Parkinson's Treatment To Biohaven For $970 Million
March 25, 2023
HighlightLL Pharma out-licensed rights to its novel oral, brain-penetrating, dual inhibitor to New Haven’s Biohaven in a deal worth up to $970 million. Biohaven will have global rights to the product...
Via
Talk Markets
Price Growth & Yield: For That Magical Combo, Leave the U.S.
March 21, 2023
Three foreign stocks, Takeda Pharmaceutical, United Microelectronics, and Coca-Cola FEMSA are showing that magical combination of growth and yield.
Via
MarketBeat
Takeda's Highest Dose Psoriasis Candidate Can Potentially Beat Bristol Myers' Approved Drug, Analyst Says
March 20, 2023
Via
Benzinga
Takeda Announces Positive Results in Phase 2b Study of Investigational TAK-279, an Oral, Once-Daily TYK2 Inhibitor, in People with Moderate-to-Severe Plaque Psoriasis
March 18, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Pharmaceutical Co. Ltd. (NYSE: TAK) Sets New 52-Week High in Friday Session
March 17, 2023
Via
Investor Brand Network
Benzinga's Top Ratings Upgrades, Downgrades For March 16, 2023
March 16, 2023
Via
Benzinga
Johnson & Johnson's Experimental Dengue Pill Shows Efficacy In Animal Studies
March 15, 2023
Via
Benzinga
HUTCHMED Announces Closing of Fruquintinib License to Takeda Outside China
March 14, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Should You Give Up on Novavax?
March 03, 2023
After a spectacular 2020 performance, Novavax's shares have plummeted.
Via
The Motley Fool
Intellia Therapeutics Stock Surges On A First-Ever In CRISPR Gene Editing
March 02, 2023
The FDA made a bold move in the CRISPR gene-editing realm.
Via
Investor's Business Daily
2 Incredibly Cheap High-Yield Dividend Stocks to Buy Now
February 28, 2023
These two high-yield dividend stocks are trading at bargain-basement prices.
Via
The Motley Fool
Takeda Presents Vedolizumab Data For Preventing Graft-Versus-Host Disease In Stem Cell Transplant Patients
February 21, 2023
Via
Benzinga
Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease (aGvHD) in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
February 18, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Is This the Telltale Sign to Sell Novavax Stock?
February 14, 2023
You won't find Novavax's latest bad news trumpeted in a press release.
Via
The Motley Fool
Takeda Completes Acquisition of Nimbus Therapeutics’ TYK2 Program Subsidiary
February 08, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.